Magnolol, an NRF2 activator with established anti-inflammatory and antioxidant effects, faces challenges with oral administration due to poor solubility and bioavailability. Jia et al. addressed this by developing a nebulized nanostructured lipid carrier formulation, which successfully prolonged lung residence and significantly regulated inflammatory and oxidative stress markers in COPD models. The gene discussed is NFE2L2; the disease is chronic obstructive pulmonary disease.